arrow
I

Ingo Hilgendorf

Deutsches Herzzentrum der Charite
H指数:39
被引数:7,074
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Speckle Tracking Analysis of the Left and Right Heart in Type 1 Diabetes Patients with End-Stage Renal Disease Awaiting Simultaneous Pancreas–Kidney Transplantation

1型糖尿病终末期肾病患者等待胰肾联合移植时左、右心室的斑点追踪分析

2026-09-290
OA
The Bone Marrow's Division of Labor in Cardiovascular Disease

骨髓在心血管疾病中的分工

2026-09-160
OAAI
Case Report: Leiomyosarcoma of the inferior vena cava presenting as a right atrial mass: the value of multimodality imaging

病例报告:下腔静脉平滑肌肉瘤表现为右心房肿块:多模态成像的价值

2026-09-010
OA
Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-challenge trial

inclisiran与bempedoic酸在高风险患者中降低低密度脂蛋白胆固醇的疗效比较:VICTORION-challenge试验

2026-08-310
OAAI
Immunological risk identified by single-cell multi-omics and cardiovascular outcomes

单细胞多组学鉴定的免疫风险与心血管结局

2026-08-140
OAAI
Plasma infrared molecular fingerprinting stratifies residual risk in coronary artery disease and reflects clonal haematopoiesis-associated biology

血浆红外分子指纹分析可分层冠状动脉疾病中的残余风险并反映与克隆性造血相关的生物学

2026-07-290
OAAI
A quantitative method to estimate free interleukin-6 among patients treated with the interleukin-6 ligand inhibitor ziltivekimab: comparison to C-reactive protein with implications for the ZEUS, HERMES, and ARTEMIS cardiovascular outcomes trials

一种用于估算接受白细胞介素-6配体抑制剂ziltivekimab治疗的患者中游离白细胞介素-6的定量方法:与C反应蛋白的比较及其对ZEUS、HERMES和ARTEMIS心血管结局试验的启示

2026-05-280
PRE
Enhanced risk for recurrent adverse cardiovascular events in homozygous carriers of the T-allele of CD40 SNP rs1883832

纯合子携带者CD40 SNP rs1883832 T等位基因的复发性不良心血管事件风险增加

2026-04-270
OAAI
Radial Versus Femoral Secondary Access in Patients Undergoing TAVI : Rationale and Design of the RADIAL-TAVI Trial

桡动脉与股动脉二次入路在经导管主动脉瓣置换术患者中的应用比较:RADIAL-TAVI试验的合理性与设计方案

2026-04-151
OAAI
Left Ventricular Global Longitudinal Strain Predicts Pacemaker-Associated Cardiomyopathy with Substantial LVEF Deterioration: Results from a Single-Center Cohort Study in Germany

左心室整体纵向应变预测起搏器相关心肌病伴显著LVEF恶化:来自德国一项单中心队列研究的结果

2026-04-060
OAAI
Expanding the Role of Implantable Loop Recorders: Diagnostic and Therapeutic Yields Across Seven Clinical Indications in 388 Real-World Patients

扩展植入式环状记录仪的应用范围:388例真实世界患者中七种临床适应症的诊断与治疗效果

2026-03-050
OAAI
A practical guide to the management of dyslipidaemia

高脂血症管理的实用指南

2026-01-080
OAAI
Low-density lipoprotein cholesterol drives multinucleated giant cell formation in response to mycobacterium bovis Bacille Calmette-Guérin

低密度脂蛋白胆固醇驱动巨噬分枝杆菌牛分枝杆菌卡介苗反应中的多核巨细胞形成

2026-01-070
OAAI
Transthoracic signs of left atrial cardiomyopathy predict presence of left atrial thromboembolic substrate
2026-01-070
OAAI
Multimodality assessment of aortic valve area in aortic stenosis: a multicenter validation study

主动脉瓣狭窄中主动脉瓣面积的多元评估:一项多中心验证研究

2025-12-010
OAAI
Endothelial CD40L serves as a pro-atherogenic adhesion receptor in the inflamed vasculature

内皮CD40L在炎症血管中充当促动脉粥样硬化的黏附受体。

2025-11-170
OAAI
GLP-1 receptor agonists as an opportunity for patients with atherosclerotic cardiovascular disease as well as obesity in Germany
2025-11-050
PRE
Spatiotemporal dynamics of the cardioimmune niche during lesion repair

损伤修复期间心免疫微环境的时空动态

2025-11-030
OAAI
Fibrin clot strength is associated with increased risk of major adverse cardiac events after TAVR

纤维蛋白凝块强度与TAVR术后主要不良心血管事件风险增加相关

2025-10-060
OA
NLRP3 mediates lipid-driven macrophage proliferation in established atherosclerosis

NLRP3介导脂质驱动的巨噬细胞增殖,在已建立的动脉粥样硬化中发挥作用

2025-09-160
OAAI